Conclusions: Reactive dicarbonyl scavenging with PPM in vivo preserves HDL function which improves insulin sensitivity and decreases atherosclerosis development. These results support the therapeutic potential of reactive dicarbonyl scavenging in the treatment of insulin resistance and atherosclerotic cardiovascular disease.
Background: Lipid peroxidation products impair HDL function and contribute to the development of atherosclerosis. Ours and other studies have shown that reactive dicarbonyls such as Isolevuglandins (IsoLG) and malondialdehyde (MDA), crosslink apoAI and impair the ability of HDL to promote cholesterol efflux. We examined whether scavenging of reactive dicarbonyls protects against the development of insulin resistance and atherosclerosis.
Methods and Results:
Here, we found that 5'-O-pentyl-pyridoxamine (PPM), a potent scavenger of reactive dicarbonyls, abolished MDA-mediated crosslinking of apoAI in HDL by 80 % (P<0.05). In addition, PPM prevented the reduction in cholesterol efflux capacity of MDA treated HDL and preserved the cholesterol efflux capacity of MPO-modified HDL in Apoe -/macrophages. Furthermore, PPM significantly improved the cholesterol efflux capacity and PON1 activity of HDL in Ldlr -/mice (P<0.05), indicating that PPM protects HDL from modifications by reactive dicarbonyls and maintains HDL function in vivo. Importantly, PPM improved hyperglycemia and insulin sensitivity in male Ldlr -/mice. Administration of 1 mg/mL of PPM, versus 1 mg/mL of the nonreactive analogue PPO, to Ldlr -/mice consuming a western diet (WD) for 16 weeks reduced the extent of proximal aortic atherosclerosis by 48% and by 46% (P<0.05) in female and male Ldlr -/mice. PPM also reduced the extent of en face aortic lesion by 52% in male Ldlr -/mice. In addition, PPM reduced pro-inflammatory enzyme MPO expression by 57.5% and the number of TUNEL positive cells by 52% (P<0.01) in atherosclerotic lesions of Ldlr -/mice. Immunohistochemistry studies revealed that PPM reduced the lesion macrophage content by 55% (P<0.05). Importantly, PPM increased M2 marker Arg1+ in macrophages of lesions and reduced the number of blood pro-inflammatory Ly6C hi monocytes and the ratio between Ly6C hi and Ly6C low , but not the numbers of Ly6C low , neutrophils in Ldlr -/mice. Similarly, treatment of Apoe -/mice on a WD for 16 weeks with PPM significantly reduced the extent of atherosclerotic lesions and also enhanced plaque stability as evidenced by a 47% increase in fibrous cap thickness and a 64.7% reduction in necrotic core area.
Introduction
Atherosclerosis is a systemic inflammatory disorder that initiates early in life and continuously builds up throughout the arterial wall over decades. Clinical and mechanistic studies have shown that many factors that facilitate the development of atherosclerosis, presenting potential targets for therapeutic modification. Although clinical trials of lowering atherogenic lipoproteins LDL-C have been demonstrated to reduce cardiovascular events, a considerable residual risk of cardiovascular disease still exists [1, 2] . This highlights the need to find novel therapeutic approaches to targeting atherosclerosis to achieve more effective reductions in cardiovascular risk.
Pleotropic functions of HDL, including anti-inflammatory function and mediation of reverse cholesterol transport are central in protecting against cardiovascular disease [3] . Cholesterol efflux capacity, a measure of HDL function in the first step of RCT, was reported to be inversely associated with measures of cardiovascular events, independent of HDL-C levels [4] [5] [6] . Recent observations support the concept that qualitative changes in HDL composition promote its atheroprotective functions [7] . HDL is also identified as an important target for treatment of type 2 diabetes (T2D) which increases atherosclerosis development. HDL promotes the uptake of glucose in skeletal muscle and increases the synthesis and secretion of insulin from pancreatic β cells and thus may have beneficial effects on glycemic control [8, 9] . Clinical studies found that reconstituted HDL increased plasma insulin and decreased plasma glucose in patients with T2D by activating AMP-activated protein kinase (AMPK) [9, 10] . Cholesteryl ester transfer protein (CETP) inhibitor torcetrapib has been shown to improve insulin sensitivity in patients with type 2 diabetes [11] .Thus, mounting evidence demonstrates HDL function is crucial in chronic inflammatory disorders, such as T2D and atherosclerosis.
Studies have shown that myeloperoxidase (MPO) promotes the formation of dysfunctional HDL and there is abundant of dysfunctional HDL in human atherosclerosis [12, 13] . Several reactive dicarbonyls including malondialdehyde (MDA), 4-oxo-nonenal, and isolevuglandins (IsoLG) are endogenously formed during lipid peroxidation. Immunization with MDA epitopes leads to atheroprotection in mouse and rabbit models [14, 15] , which highlights the importance of MDA epitopes in atherosclerosis. Synthetic MDA-lysine can promote monocyte activation and vascular complications via induction of inflammatory pathways [16] . Modifying apoAI by MDA blocks cholesterol efflux from macrophages [17] . In addition, dysfunctional apoAI is present in human atherosclerotic lesions [13] including MDA modified HDL [17] . In addition, our recent studies showed that IsoLG modification of HDL reduces the cholesterol efflux and antiinflammatory capacity [18] . Importantly, HDL from familial hypercholesterolemic (FH) versus control subjects contains significantly more IsoLG adducts which likely contribute to the dysfunctional FH-HDL [18] . Taken together, mounting evidence supports the concept that HDL atheroprotective function can be impaired and that reactive dicarbonyls such as MDA and IsoLG, contribute to HDL dysfunction, insulin resistance, and the development of atherosclerosis.
In the current studies, we utilized a potent reactive dicarbonyl scavenger, 5'-O-pentylpyridoxamine (PPM), to dissect the role of reactive carbonyl species in causing HDL dysfunction in promoting the development of insulin resistance and atherosclerosis. Our earlier studies demonstrated that the PPM versus lysine residues reacts nearly 2000 times faster with the reactive dicarbonyl, IsoLG, thereby preventing lysine modification [19] . We found that scavenging reactive dicarbonyls with PPM prevents MPO-mediated impairment of HDL cholesterol efflux capacity in vitro, and importantly, in vivo administration of PPM to hypercholesterolemic mice increased HDL cholesterol efflux capacity and PON1 activity without affecting plasma cholesterol levels. Consistent with the effects on HDL function, administration of PPM to Ldlr -/mice consuming a western diet reduced insulin resistance, atherosclerotic lesion extent, lesion M1 macrophages, blood Ly6C hi monocytes, and lesion TUNEL positive macrophages. Furthermore, PPM treatment increased the plaque fibrous cap thickness and reduced the necrotic area thereby improving plaque stability. Taken together, our results suggest that reactive dicarbonyl scavenging has high therapeutic potential in preventing HDL dysfunction, insulin resistance, and atherosclerosis development.
Material and Methods
Mice -Apoe -/and Ldlr -/mice were purchased from Jackson Laboratories (Bar Harbor, ME).
Mice were maintained in micro-isolator cages with ad libitum access to a rodent chow diet Reactive dicarbonyl scavengers -For animal studies, female and male Ldlr -/mice on a western diet (WD) were treated with water alone or with either 1 g/L of PPM or the inactive analogue, pentylpyridoxine (PPO), for 16 weeks after pretreatment of mice on chow diet with PPM or PPO for 2 weeks, respectively. The effects of reactive dicarbonyl scavenging on atherosclerosis was also examined in male Apoe -/mice that were on a WD and treated with water alone or with 1g/L of PPM for 16 weeks after pretreatment of the mice on a chow diet with water alone or PPM for 2 weeks.
Reagents -Fresh human HDL was isolated from normal subjects by sequential density ultracentrifugation as previously described [18] . Isolation of peritoneal macrophages -Peritoneal macrophages were isolated from 10 week-old Apoe -/mice 4 days after injection of 5% of thioglycollate. Peritoneal cells were collected by lavage using Ca 2+ and Mg 2+ free PBS and then centrifuged and re-suspended in DMEM containing 10% heat-inactivated FBS and 100 units/ml penicillin/streptomycin. Cells were plated onto 24-well culture plates (1*10 6 cells/well) and allowed to adhere for 2 h. Non-adherent cells were removed by washing two times with DPBS, and adherent macrophages were used for experiments.
Serum lipid measurements, lipid profiling of FPLC-separated lipoprotein fractions and ApoB-
depleted serum preparation -Serum total cholesterol and triglyceride (TG) levels were measured by the enzyme-based method (Sigma) after overnight fasting. Lipid profiling of FPLCseparated lipoprotein fractions was done using gel filtration analysis with s Superose6 column on a Waters 600 FPLC system. 100μl of aliquot of mouse serum was injected onto the column and separated with a buffer containing 0.15 M NaCl, 0.01 M Na2HPO4, and 0.1mM EDTA (pH 7.5), at a flow rate of 0.5 mL/min. cholesterol levels were determined by the enzyme-based method (Sigma) after collecting the fractions [22] . ApoB-depleted serum was prepared as described [23, 24] . Briefly, to precipitate apoB-containing lipoproteins from serum, 400 μL of PEG 8,000 (20% in 200 mM glycine) was added to 1 ml serum, incubated for 15 min at room temperature, and then centrifuged at 1,900g for 20 min. The supernatant containing the apoBdepleted serum was collected and used for the cholesterol efflux experiments.
Measurement of PON1 activity-The PON1 activity was measured using the EnzCheck PON1 activity kit (Thermo Fisher Scientific). PON1 standards and diluted mouse serum samples were prepared in TSC buffer (20mM Tris-HCl, 150mM NaCl and 2mM CaCl 2 , pH 8.0). The samples and standards were then incubated for 30 min with TSC buffer containing 100µM substrate.
Fluorescence intensity was then measured using Biotek's Synergy MX Microplate reader (Winooski, VT) with Gen 5 software at excitation wavelength of 368nm and an emission wavelength of 460nm after 30 min of incubation at 37 0 C. Measurement of HDL capacity to reduce macrophage cholesterol -To measure the capacity of HDL to reduce macrophage cholesterol content, Apoe -/macrophages were isolated and incubated for 48 h with DMEM containing acetylated LDL (40 μg/ml). The cells were then washed and incubated for 24 h in DMEM supplemented with HEPES in the presence of 50 ug/mL human HDL, modified HDL, or 2.8% apoB-depleted serum. Cellular cholesterol was measured before and after incubation with cholesterol acceptor using an enzymatic cholesterol assay as described [25, 26] .
Western blotting -Samples were incubated with β-mercaptoethanol and loading buffer for 10 min at 55 0 C and then resolved by NuPAGE Bis-Tris electrophoresis using 4-12% gels for 1.5 h.
The proteins were transferred onto PVDF membranes (Amersham Bioscience) at 150 V for 1.5 h. Membranes were blocked with 5% milk at room temperature for 2 h and incubated with primary goat antibodies specific to human apoAI overnight at 4 o C. The secondary antibodies conjugated with HRP were incubated with the membranes for 2 h at room temperature. Protein bands were visualized with ECL western blotting detection reagents (GE Healthcare) and quantified using ImageJ software (NIH).
Glucose tolerance test (GTT) and insulin tolerance test (ITT) -Insulin levels were measured by ELISA. For the GTT, mice were fasted for 4h, and 10 µL blood was taken from the tail vein for measurement of baseline levels. Mice were then injected with 1g/kg of glucose. Blood samples were taken at 15, 30, 45, 60, 90, 120 minutes after the glucose challenge and analyzed for blood glucose with a clinical meter [27] . For ITT, mice were fasted for 4h, and after taking a baseline blood sample, the mice were injected with insulin (0.5U/kg). Blood samples were then taken at 15, 30, 60, 90, 120 minutes after insulin challenge and analyzed for blood glucose with a clinical meter [27] . The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the equation fasting insulin (μU/ml) × fasting plasma glucose (mmol/liter)/22.5.
Measurement of atherosclerotic lesions -Aortas were flushed with PBS through the left ventricle and the entire aorta was dissected and en face was stained with Sudan IV as described. The extent of atherosclerosis was examined in Oil-Red-O stained cross-sections of the proximal aorta (15 alternate 10 µm cryosections for each mouse aorta). Images of the proximal and distal aorta lesions were analyzed using the KS300 imaging system (Kontron Electronik GmbH) [28] .
HE staining of liver tissue-During dissection of the mice, livers were isolated, weighed, and stored for further analyses. After overnight fixation in 4% formaldehyde, tissues were embedded in paraffin, and 5 µm sections were collected and stained with hematoxylin & eosin (HE). Digital images were taken at a magnification of 200 using Olympus IX81 fluorescence microscope with SlideBook 6 (Intelligent-Image) software. The fat content of the liver was scored according to the content of fat droplets with the following scores: 0, no fat droplets; 1, very few fat droplets; 2, few fat droplets; 3, multiple fat droplets; and 4, many fat droplets [29] .
Measurement of prostaglandin(PG) metabolites -Male LDLR-/-mice were given vehicle (n=8), 1 mg/mL PPM (n=8) for 8 weeks. Urine was collected for 6 hrs in metabolic cages with 2 mice per cage after 8 weeks of treatment with PPM and analyzed by GC/MS for 2,3-dinor-6-ketoPGF1 (2,3DN) and 11-dehydro Immunohistochemical (IHC) staining of atherosclerotic lesions -Immunofluorescence staining was used to examine protein levels in atherosclerotic lesions [28] . Briefly, 5 µm cross-sections of the proximal aorta were fixed in cold acetone (Sigma), blocked with 5% goat serum dilution (GSD), and incubated overnight at 4ºC with primary antibody to MOMA2, MPO, arginase 1 (Arg1), or C-C chemokine receptor2 (CCR2). After incubation for 1h at 37 ºC with the fluorescent labeled secondary antibody, the nuclei were stained with DAPI. The images were captured using an Olympus IX81 fluorescence microscope with SlideBook 6 (Intelligent-Image) software and quantified using ImageJ software (NIH).
Analysis of lesion apoptosis-The apoptotic cells in atherosclerotic lesion were measured by
TUNEL staining of cross-sections of the proximal aorta. Briefly, 5 μm sections were fixed in 2% paraformaldehyde, treated with 3% citric acid, and then stained using the in situ TMR red cell death detection kit (Roche Applied Science). TUNEL-positive (TUNEL+) cells were counted in proximal aortic sections as described [28] .
Masson's Trichrome staining-Masson's Trichrome staining procedure (Sigma) was used for measurement of lesion necrotic core size and fibrous cap thickness as previously described [30] . Briefly, 5 µm sections of the proximal aorta were fixed for 30 min with Bouin's solution and stained with hematoxylin for nuclei (black). Biebrich scarlet solution and phosphotungstic/phosphomolybdic acid were added to stain cytoplasm (red), and Aniline blue solution was applied to stain collagen (blue). Images were obtained and analyzed for fibrous cap thickness and % necrotic area using ImageJ software (NIH).
Flow analysis white blood cells -To measure the numbers of blood neutrophils, Ly6C hi monocytes, and Ly6C low monocytes in Ldlr -/mice, blood cells were collected and stained with a cocktail of antibodies targeting these cells [28] . Briefly, 100 µL of blood was collected using Natelson Blood collection tubes, and then incubated with Fc inhibitor CD16/32 for 10 min at RT.
Lysis buffer (3 mL) was pre-warmed at 37 o C and added to the blood samples and incubated at room temperature for 30 mins to lyse red blood cells. Samples were centrifuged at 1200 rpm for 10 mins, and the cell pellets were re-suspended with 300 ul of FACS buffer (2% FBS in PBS). 
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Results
First, we examined the effects of PPM on MDA-mediated apoAI crosslinking and impairment of net cholesterol efflux capacity. Modification of HDL with 0.25 mM MDA increased the degree of apoAI crosslinking (Figures 1A and 1B) and decreased the capacity of the HDL to reduce macrophage cholesterol by 64% ( Figure 1C ). Addition of either 1 mM or 5 mM of PPM significantly decreased the MDA-mediated crosslinking of apoAI ( Figures 1A and 1B) and
improved the impairment of HDL net cholesterol efflux capacity ( Figure 1C ). In addition, MPOmediated HDL modification reduced the net cholesterol efflux capacity by 54.5% and PPM (1 mM) prevented any impairment in cholesterol efflux ( Figure 1D ). More importantly, administration of PPM to Ldlr -/mice on a western diet increased the net cholesterol efflux capacity of HDL and enhanced the their HDL associated PON1 activity ( Figures 1E and 1F) .
Studies have shown that Ldlr -/mice develop insulin resistance when consuming a WD which likely contributes to the development of atherosclerosis [31] . As macrophage inflammation is modulated by HDL, we next examined the effects of scavenging reactive dicarbonyls on atherosclerotic lesion macrophage inflammatory markers.
Immunohistochemical staining of the proximal aortic sections from male Ldlr -/mice demonstrates that compared to water alone, PPM increased the number of anti-inflammatory Arg1 positive M2 macrophages by 120% ( Figures 5A and 5B) , and decreased the numbers of pro-inflammatory CCR2 positive macrophages by 58% ( Figures 5C and 5D ). In addition, PPM treatment reduced the expression of proinflammatory, MPO by 58% ( Figures 5E and 5F ).
Consistent with reactive dicarbonyl scavenging reducing atherosclerotic lesion inflammation, PPM versus vehicle treatment decreased the number of apoptotic macrophages as evidenced by TUNEL staining in the proximal aortic lesion in Ldlr -/mice ( Figures 6A and 6B) . PPM reduced the MDA-HDL, MDA-LDL content in these mice on WD for 16 weeks (Figure 6C and   6D ). In consistent, PPM decreased the levels of MDA in lesions of Ldlr -/mice ( Figure 6E and 6F). Similar results were observed in male Ldlr -/mice ( Supplemental Figures 2A and 2B ). PPM also reduced the inflammatory cytokine IL1β expression levels determined by ELISA ( Figure   6G ). Furthermore, examination of the effects on plaque necrosis and fibrous cap thickness demonstrates that PPM promotes plaque stability. Compared to vehicle, PPM decreased the necrotic area by 52.6% and increased the fibrous cap thickness by 41.7% in female Ldlr -/mice ( Figures 7A-7C) . Similarly, PPM administration to Apoe -/mice decreased the number of dead macrophages in the proximal aortic lesions by 60% (Supplemental Figures 1D and 1E ). PPM treatment reduced the necrotic area by 64.7% and increased the fibrous cap thickness by 47% in the proximal aortic lesion of male Apoe -/mice (Supplemental Figures 1F-1H ). Importantly, treatment with PPM did not impact levels of urinary prostaglandin metabolites of prostacyclin, thromboxane, indicating that PPM does not result in significant inhibition of cyclooxygenase in mice in vivo (Supplemental Figure 4) . Figure 8 ). Importantly, reactive dicarbonyl scavenging enhanced plaque stability as substantiated by the increased fibrous cap thickness and the decreased necrotic core ( Figure 6 & Figure 7) . Thus, our studies suggest that reactive dicarbonyl scavenging with PPM has therapeutic potential to improve insulin sensitivity and reduce the risk of clinical events by decreasing atherosclerosis development and plaque instability.
To the best of our knowledge, this is the first experimental study of how rescuing HDL functionality rather than raising HDL-C levels improves insulin sensitivity and reduces atherosclerosis in hypercholesterolemic model. We found that PPM treatment reduces atherosclerosis development without changing plasma cholesterol levels (Figure 3 & 4) in hypercholesterolemic Ldlr -/and Apoe -/mice making it likely that the protection against atherosclerosis results from reactive dicarbonyl scavenging preserving normal molecular functions. HDL protects against atherosclerosis via a number of functions including mediating cholesterol efflux and preventing inflammation, and studies have demonstrated that markers of HDL dysfunction versus HDL-C levels are a better predictor of cardiovascular event risk [4] [5] [6] .
Our recent studies showed that IsoLG modification of HDL reduces the cholesterol efflux and anti-inflammatory capacity and FH-HDL compared to control HDL contains more IsoLG-HDL adducts [18] . In addition, MDA modification of lipid-free apoAI impairs ABCA1 mediated cholesterol efflux and MDA-HDL adducts are present in human atherosclerotic lesions [17] .
Consistent with these studies, we show that MDA modification of HDL promotes apoAI crosslinking and decreases it ability to mediate the net efflux of cholesterol from macrophage foam cells ( Figures 1A-C ). In addition, PPM treatment of Ldlr -/mice decreased MDA content of HDL ( Figure 6C) . Importantly, our studies demonstrate that in vivo scavenging of reactive dicarbonyls with PPM increases HDL net cholesterol efflux capacity and PON1 activity (Figures 1) which likely contributes to the atheroprotective effects of reactive carbonyl scavenging in the setting hypercholesterolemia. Consistent with the increased HDL PON1 activity, reactive dicarbonyl scavenging with PPM decreased the MDA-LDL adducts in Ldlr -/mice which also probably decreases atherosclerotic lesion formation ( Figure 6D ). Besides the atheroprotective effects of decreasing HDL dysfunction and LDL modification, reactive dicarbonyl scavenging likely acts directly in the arterial wall to reduce atherosclerosis as PPM decreased the MDA content of atherosclerotic lesions in Ldlr -/mice ( Figure 6 ).
Studies have demonstrated that Ly6C hi monocytes dominate hypercholesterolemia-associated monocytosis in mice and give rise to inflammatory macrophages in the progressing atheroma [32] . In addition, infiltrating Ly6C hi monocytes drive chronic, unresolved inflammation and impair tissue repair in mouse models of diabetes mellitus [35] . Furthermore, humans with hypercholesterolemia have increased numbers of CD14 ++ CD16 + monocytes (Ly6C hi monocytes in mice) [36] [37] [38] [39] . Importantly, there is growing evidence that Ly6C hi monocytosis promotes plaque instability in humans. In a large clinical study of 951 patients undergoing elective coronary angiography, increased numbers of intermediate CD14 ++ CD16 + monocytes independently predicted cardiovascular death, myocardial infarction, and stroke [40] . Our finding that PPM reduces Ly6C hi monocytosis in response to hypercholesterolemic stress provides a novel atheroprotective mechanism whereby dicarbonyl scavenging decreases atherosclerotic lesion formation and plaque destabilization without decreasing plasma cholesterol. It is likely that the effects of PPM on monocytosis are from dicarbonyl scavenging at level of hematopoietic stem/progenitor cells (HSPC). Studies have shown that hypercholesterolemia induces oxidative stress in HSPC causing enhanced p38 and Notch1 signaling resulting in markedly increased proliferation [41] . In addition, treatment of hypercholesterolemic Apoe -/mice with antioxidants decreases HSPC proliferation [41] . It is also likely that the improvement in HDL function with PPM treatment contributes to the reduction in inflammatory monocytosis as HDL/apoAI reduces the proliferation of HSPC by mediating cholesterol efflux [42] .
In the atherosclerotic lesions, inflammatory conditions induce the preferential conversion of infiltrating Ly6C hi monocytes into proinflammatory M1 phenotype macrophages which are prominent in the progression of the atheroma and the development of unstable plaques [43] .
Indeed, recent studies suggest that inflammation is a residual risk to cardiovascular disease as studies have shown that humans treated with the IL-1β monoclonal antibody, canakinumab, had a significantly lower rate of recurrent cardiovascular events which were independent of cholesterol lowering [44] . Our studies show that reactive dicarbonyl scavenging reduced the IL-1β levels and decreased the number of inflammatory macrophages as evidenced by the reduced expression of MPO and CCR2 in Ldlr-/-mice( Figure 5 and Figure 6 ). Pharmacologic inhibition of MPO decreases atherosclerosis [45, 46] and MPO promotes plaque instability by modifying extracellular matrix protein, inhibiting NO availability, and reducing endothelial glycocalyx thickness [47] [48] [49] . CCR2 deficiency also reduces atherosclerosis [50] , which is consistent with CCR2 being required for Ly6C hi monocyte recruitment to atherosclerotic lesions.
In addition, CCR2 expression on circulating monocytes is associated with vascular inflammation in humans at risk for cardiovascular disease [51] . Consistent with reactive dicarbonyl scavenging impacting monocyte infiltration, our studies show that mice treated with PPM had reduced numbers of macrophages in their atherosclerotic lesions ( Figure 3 ). Also consistent with dicarbonyl scavenging reducing inflammation, PPM treatment increased the atherosclerotic lesion anti-inflammatory M2 macrophage content as evidenced by the increased Arg1 expression ( Figure 5 ). Besides reactive dicarbonyl scavenging directly affecting macrophage inflammation, the enhanced HDL function induced by PPM treatment likely contributes to the increased lesional M1 to M2 macrophage phenotypic switch.
Studies have shown that HDL abrogates the induction of macrophages to an M1phenotype, as demonstrated by a reduction in the cell surface markers CD192 and CD64, as well as by decreased expression of MCP-1 (CCL2) [52] . HDL inhibits ERK1/2 and STAT3 phosphorylation in M1 macrophages [52] . HDL also increases expression of the M2 markers Arg1 and Fizz-1 via a mechanism requiring STAT6 [53] . It is worth noting that the effects of HDL on these signaling pathways in regulation of macrophage phenotype are intimately linked to its cholesterol efflux function [54, 55] which is enhanced by reactive dicarbonyl scavenging in vivo (Figure 1) . Similar to other studies, [31] administration of a western diet to Ldlr -/mice caused the development of insulin resistance. Interestingly, we found that reactive dicarbonyl scavenging improved insulin sensitivity in the Ldlr -/mice consuming a western diet ( Figure 2 ). Evidence has mounted that HDL improves insulin resistance. Short term administration of reconstituted HDL into patients with T2D reduced fast glucose levels and improved glucose metabolism. In addition, HDL via its cholesterol efflux function reduces the fat deposition in the liver suggesting that the PPM effects on cholesterol efflux contributed to the improved insulin sensitivity [8, 9] . Furthermore, studies have shown that apoAI promotes activation of AMPK in skeletal muscle and liver which increases fatty acid β-oxidation and glucose uptake [9, 56] . To date, the apoAI receptor signaling pathways that operate in AMPK activation are unknown, but studies suggest that interaction with ABCA1 or SR-BI may be involved [57] . In this regard, both IsoLG-and MDA-apoAI adduct formation markedly reduce ABCA1 mediated efflux [13] [18] , which requires apoAI interaction and signaling. In addition, oxidation of HDL alters interaction with SR-BI and severely impairs SR-BI signaling and function [58] . Oxidation of HDL also increases HDL internalization and apoAI degradation likely reducing apoAI function [59] . Taken together, it is plausible that reactive dicarbonyl scavenging rescues apoAI from degradation thereby preserving beneficial HDL/apoAI signaling pathways.
Understanding the mechanism through which scavenging reactive dicarbonyls improves insulin 
